Sexual Health Testing Market Analysis

Sexual Health Testing Market Analysis

To get key market trends

  Download Free Sample

Based on device type, the sexual health testing market is segmented into laboratory devices and point of care (PoC) devices. The laboratory devices segment is further bifurcated into PCR (polymerase chain reaction), flow cytometers, enzyme linked immunosorbent assay (ELISA), and others. The point of care (PoC) devices segment is further subdivided into rapid diagnostic kits and microfluidics & immunochromatographic testing (ICT). The laboratory devices segment held the largest revenue size over USD 60 billion in 2022 and is estimated to witness significant growth more than USD 100 billion by 2032. Laboratory tests often provide higher accuracy and sensitivity compared to POC tests. They are designed to detect and quantify specific markers, such as antibodies or antigens, associated with sexually transmitted infections (STIs).
 

Laboratory tests undergo rigorous validation and quality control measures, ensuring reliable and precise results. Furthermore, an increase in the availability of device type coupled with several other businesses working towards creating innovative technology will support the segment's revenue growth.
 

STD diagnostics market is bifurcated based on the application including chlamydia, gonorrhoea, syphilis, genital herpes, hepatitis B, HIV/AIDS, others. The chlamydia segment dominated the market and is anticipated to grow over USD 36 billion by 2032. Chlamydia is one of the most commonly reported sexually transmitted infections (STIs) worldwide, and its prevalence has been increasing over the years. For instance, according to the World Health Organization (WHO), an estimated 127 million new cases of chlamydia occur, annually.
 

The sexual health testing market is segmented by end-use into hospitals, diagnostic centers, and others. Diagnostic centers segment dominated the global market accounting for more than 52% business share in 2022 and is estimated to witness significant revenue over USD 82 billion by 2032. The diagnostic centers segment is anticipated to hold high growth potential during the analysis period. Factors such as surging laboratory tests and rising preference towards diagnostics laboratories due to presence of advanced technologies and cost-effective treatment will fuel market growth. Additionally, these centers provide early and accurate disease diagnosis and patient management, thus, anticipated to augment the segment trends.
 

U.S. sexual health testing market accounted for more than USD 33 billion in 2022 and will grow momentously more than USD 55 billion by 2032. The affordability of sexual health testing among the target population base and ongoing technological developments are primarily responsible for the growth of the STD diagnostics market in United States. Further, the region's high healthcare spending on health care management and rising disposable income will propel the expansion of the North America market. Also, the substantial presence of well-established market participants and the favourable regulatory environment result in a number of product approvals and launches, particularly in the U.S.